Austin LA, Smith JS, Nahas DD, Danzinger A, Secore S, ODonnell G, et al
Following your test, your data will be analysed and results written up into a report
Angew Chem Int Ed 49:68856888 Schultz E (1997) Ionization or dissociation
British healthcare providers' focus on evidence-based medicine, cost-effectiveness, and patient outcomes creates steady demand for proven GLP-1 therapies
So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
